Inflammatory cytokine production in intestinal macrophages

Inflammatory cytokine production in intestinal macrophages refers to the pathological process where resident or recruited macrophages in the gastrointestinal mucosa secrete high levels of pro-inflammatory mediators (Bain & Schridde, 2018, Nature Reviews Immunology). Under normal physiological conditions, intestinal macrophages maintain an 'inflammation-anergic' phenotype, which is crucial for mucosal tolerance to commensal microbiota (Smith et al., 2011, Journal of Immunology). However, in diseases such as Crohn's disease and ulcerative colitis, these cells undergo aberrant activation, releasing cytokines like Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) that drive chronic tissue damage and inflammation (Neurath, 2014, Nature Reviews Immunology). While this process is a biological phenotype rather than a single molecular target, it is the primary focus of many IBD therapies that aim to neutralize these cytokines or block the signaling cascades, such as the JAK/STAT pathway, that facilitate their production (Danese et al., 2019, Lancet). Monitoring this process through biomarkers like fecal calprotectin is essential for assessing disease activity and the clinical efficacy of biological and small-molecule therapies (Walsh et al., 2016, Alimentary Pharmacology & Therapeutics).

Other names

Intestinal macrophage activationMacrophage-derived cytokine releaseGut macrophage inflammatory responsePro-inflammatory cytokine production in the gut

Therapeutic intervention involves the neutralization of secreted pro-inflammatory cytokines (e.g., TNF-alpha, IL-12, IL-23) using monoclonal antibodies or the inhibition of intracellular signaling pathways, such as the Janus kinase (JAK) pathway, which are required for cytokine gene expression and secretion.